JP7342005B2 - エフェクター機能が減少した抗ｓｉｇｌｅｃ－７抗体 - Google Patents

エフェクター機能が減少した抗ｓｉｇｌｅｃ－７抗体 Download PDF

Info

Publication number
JP7342005B2
JP7342005B2 JP2020538029A JP2020538029A JP7342005B2 JP 7342005 B2 JP7342005 B2 JP 7342005B2 JP 2020538029 A JP2020538029 A JP 2020538029A JP 2020538029 A JP2020538029 A JP 2020538029A JP 7342005 B2 JP7342005 B2 JP 7342005B2
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
siglec
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020538029A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019140273A5 (https=
JP2021511298A (ja
JP2021511298A5 (https=
Inventor
ベビントン クリストファー
コーバー ウター
トマシェビッチ ネナド
Original Assignee
アラコス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラコス，インコーポレイティド filed Critical アラコス，インコーポレイティド
Publication of JP2021511298A publication Critical patent/JP2021511298A/ja
Publication of JPWO2019140273A5 publication Critical patent/JPWO2019140273A5/ja
Publication of JP2021511298A5 publication Critical patent/JP2021511298A5/ja
Application granted granted Critical
Publication of JP7342005B2 publication Critical patent/JP7342005B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2020538029A 2018-01-11 2019-01-11 エフェクター機能が減少した抗ｓｉｇｌｅｃ－７抗体 Active JP7342005B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616317P 2018-01-11 2018-01-11
US62/616,317 2018-01-11
PCT/US2019/013316 WO2019140273A1 (en) 2018-01-11 2019-01-11 Anti-siglec-7 antibodies having reduced effector function

Publications (4)

Publication Number Publication Date
JP2021511298A JP2021511298A (ja) 2021-05-06
JPWO2019140273A5 JPWO2019140273A5 (https=) 2022-02-07
JP2021511298A5 JP2021511298A5 (https=) 2022-02-07
JP7342005B2 true JP7342005B2 (ja) 2023-09-11

Family

ID=67219179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020538029A Active JP7342005B2 (ja) 2018-01-11 2019-01-11 エフェクター機能が減少した抗ｓｉｇｌｅｃ－７抗体

Country Status (6)

Country Link
US (1) US11912766B2 (https=)
EP (1) EP3737410A4 (https=)
JP (1) JP7342005B2 (https=)
AU (1) AU2019208025A1 (https=)
CA (1) CA3087968A1 (https=)
WO (1) WO2019140273A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
WO2023192992A2 (en) * 2022-03-31 2023-10-05 The Wistar Institute Of Anatomy And Biology Bispecific natural killer engagers that target siglec-7
WO2023192993A2 (en) * 2022-03-31 2023-10-05 The Wistar Institute Of Anatomy And Biology Antibodies against human siglec-7 and use thereof for immunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038064A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
WO2017040301A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
WO2017153433A1 (en) 2016-03-08 2017-09-14 Innate Pharma Siglec neutralizing antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120815A2 (en) 2006-04-12 2007-10-25 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
CN101687924A (zh) * 2007-07-04 2010-03-31 株式会社未来创药研究所 抗Muc17抗体
PE20190658A1 (es) * 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
CA2896076C (en) * 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
MX383594B (es) * 2014-08-07 2025-03-14 Daiichi Sankyo Co Ltd Anticuerpo anti-orai1.
BR112018010172A2 (pt) * 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
WO2017123745A1 (en) 2016-01-12 2017-07-20 Palleon Pharma Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
JP7137563B2 (ja) * 2016-08-05 2022-09-14 アラコス，インコーポレイティド がん治療用の抗Ｓｉｇｌｅｃ－７抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038064A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
WO2017040301A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
WO2017153433A1 (en) 2016-03-08 2017-09-14 Innate Pharma Siglec neutralizing antibodies

Also Published As

Publication number Publication date
CA3087968A1 (en) 2019-07-18
WO2019140273A1 (en) 2019-07-18
US11912766B2 (en) 2024-02-27
US20210054072A1 (en) 2021-02-25
EP3737410A1 (en) 2020-11-18
EP3737410A4 (en) 2022-04-20
JP2021511298A (ja) 2021-05-06
AU2019208025A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
JP7137563B2 (ja) がん治療用の抗Ｓｉｇｌｅｃ－７抗体
US20240018257A1 (en) Antibodies specific to human poliovirus receptor (pvr)
JP7342005B2 (ja) エフェクター機能が減少した抗ｓｉｇｌｅｃ－７抗体
CA3100829A1 (en) Antibodies specific for gucy2c and uses thereof
KR20210009308A (ko) 인간 넥틴4에 특이적인 항체
KR20230121772A (ko) Ceacam5 및 cd47에 대한 이중특이적 항체
WO2021139682A1 (en) Anti-galectin-9 antibody and uses thereof
WO2022013775A1 (en) Therapeutic antibodies and their uses
US20240392000A1 (en) Methods of treating cancers associated with immunosuppressive b cells
WO2024041651A1 (en) Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies
US20250042996A1 (en) Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
TW202523694A (zh) 抗muc16抗體及其用途
KR20260013511A (ko) 암 치료를 위한 조합 요법
TW202446419A (zh) 使用抗ｏｘ４０抗體與抗ｐｄ１抗體之組合的癌症治療方法
IL325132A (en) Antibodies directed against tigit and their uses
HK40001896B (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896A (en) Antibodies specific to human poliovirus receptor (pvr)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230830

R150 Certificate of patent or registration of utility model

Ref document number: 7342005

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150